Our previous study and others' studies have shown that SPRY2 expression is down-regulated in human ovarian cancer and that patients with low SPRY2 expression have significantly poorer survival than those with high SPRY2 expression [25–28]. Here, SPRY2 is linked to ovarian cancer.